← SynDRA
AFURESERTIB
SynDRA canonical compound SYN0034465 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | AKT1 | AKT2 | AKT3 |
| Mechanism of action | AKT inhibitor |
All known targets
Mechanisms of action (all sources)
- AKT2 INHIBITOR
- Serine/threonine-protein kinase AKT inhibitor
- AKT3 INHIBITOR
- AKT1 INHIBITOR
Cross-references
Synonyms
- GSK-2110183
- ASB-183
- ASB183
- GSK-2110183C
- GSK2110183
- GSK2110183C
- GSK 2110183
- Afuresertib [USAN]
- Afuresertib (GSK2110183)
- Afuresertib (USAN)
- 8739X25QI3
- 2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-
- N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide
- Afuresertib [USAN:INN]
- UNII-8739X25QI3
- 2-Thiophenecarboxamide, N-[(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-
- N-((1S)-1-(aminomethyl)-2-(3-fluorophenyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide
- N-((2S)-1-AMINO-3-(3-FLUOROPHENYL)PROPAN-2-YL)-5-CHLORO-4-(4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL)THIOPHENE-2-CARBOXAMIDE
- N-[(1S)-1-(Aminomethyl)-2-(3-fluorophenyl)ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide
- N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide
- AFURESERTIB [INN]
- AFURESERTIB [WHO-DD]
- SCHEMBL187686
- GTPL7890
- CHEMBL2219422
- DTXSID60146711
- CHEBI:131168
- BCP08435
- EX-A1574
- BDBM50502477
- NSC778305
- NSC781255
- NSC800109
- NSC829868
- s7521
- ZINC43197674
- CCG-268972
- CS-3384
- DB11648
Look up AFURESERTIB in the interactive SynDRA portal →